Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Thall

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Statistics in Medicine|May 1, 1988
Optimal two-stage designs for clinical trials with binary responseP F Thall, R Simon, S S Ellenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabineE Estey, P F Thall, S Pierce, et al.
Statistics in Medicine|June 11, 1999
Accrual strategies for phase I trials with delayed patient outcomeP F Thall, J J Lee, C H Tseng, et al.
Statistics in Medicine|September 15, 1994
An optimal three-stage design for phase II clinical trialsL G Ensign, E A Gehan, D S Kamen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2017
Phase I-II clinical trial design: a state-of-the-art paradigm for dose findingF Yan, P F Thall, K H Lu, et al.
Journal of Neuro-Oncology|January 1, 1996
Prognostic significance of preoperative MRI scans in glioblastoma multiformeM A Hammoud, R Sawaya, W Shi, et al.
American Journal of Respiratory and Critical Care Medicine|September 10, 1998
Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unitK J Price, P F Thall, S K Kish, et al.
Leukemia|June 9, 1999
Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapyE H Estey, P F Thall, P Reed, et al.
Leukemia & Lymphoma|August 26, 1998
Serum cytokine levels in infectious mononucleosis at diagnosis and convalescenceV Wright-Browne, A M Schnee, M A Jenkins, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Statistics in Medicine|May 1, 1988
Optimal two-stage designs for clinical trials with binary responseP F Thall, R Simon, S S Ellenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabineE Estey, P F Thall, S Pierce, et al.
Statistics in Medicine|June 11, 1999
Accrual strategies for phase I trials with delayed patient outcomeP F Thall, J J Lee, C H Tseng, et al.
Statistics in Medicine|September 15, 1994
An optimal three-stage design for phase II clinical trialsL G Ensign, E A Gehan, D S Kamen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2017
Phase I-II clinical trial design: a state-of-the-art paradigm for dose findingF Yan, P F Thall, K H Lu, et al.
Journal of Neuro-Oncology|January 1, 1996
Prognostic significance of preoperative MRI scans in glioblastoma multiformeM A Hammoud, R Sawaya, W Shi, et al.
American Journal of Respiratory and Critical Care Medicine|September 10, 1998
Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unitK J Price, P F Thall, S K Kish, et al.
Leukemia|June 9, 1999
Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapyE H Estey, P F Thall, P Reed, et al.
Leukemia & Lymphoma|August 26, 1998
Serum cytokine levels in infectious mononucleosis at diagnosis and convalescenceV Wright-Browne, A M Schnee, M A Jenkins, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Pageof 6